Brokers Offer Predictions for ZVRA Q1 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – HC Wainwright issued their Q1 2025 earnings estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Thursday, March 13th. HC Wainwright analyst O. Livnat forecasts that the company will post earnings per share of ($0.23) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at $0.01 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The firm had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

ZVRA has been the topic of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Canaccord Genuity Group lifted their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Thursday. Finally, Guggenheim lifted their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $22.14.

Zevra Therapeutics Stock Up 4.7 %

Shares of ZVRA stock opened at $8.31 on Friday. The company has a market capitalization of $449.70 million, a price-to-earnings ratio of -4.22 and a beta of 1.98. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76. The company’s fifty day moving average price is $7.93 and its 200-day moving average price is $8.16. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Insider Transactions at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the transaction, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the transaction, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock worth $674,176 in the last three months. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of large investors have recently made changes to their positions in ZVRA. Adage Capital Partners GP L.L.C. boosted its stake in shares of Zevra Therapeutics by 462.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock worth $30,441,000 after purchasing an additional 3,001,000 shares during the period. FMR LLC boosted its position in Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after buying an additional 2,312,384 shares during the period. AIGH Capital Management LLC purchased a new stake in Zevra Therapeutics in the 4th quarter valued at about $6,577,000. Stonepine Capital Management LLC purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at about $4,858,000. Finally, Vestal Point Capital LP purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at about $3,644,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.